{Reference Type}: Journal Article
{Title}: A Case of Secondary Growth Hormone Deficiency that Developed into Cirrhosis after Several Years of Interrupted Growth Hormone Replacement Therapy.
{Author}: Sueki A;Kaya D;Nagamatsu S;Yamamoto C;Ohta K;Matsuo Y;Nishio Y;Komeda Y;Kikukawa S;Matsuura K;Matsuo H;Uejima M;Moriya K;
{Journal}: Intern Med
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 27
{Factor}: 1.282
{DOI}: 10.2169/internalmedicine.3896-24
{Abstract}: This case report describes a patient who received hormone replacement therapy for secondary panhypopituitarism and subsequently developed diabetes. His physician decided to discontinue growth hormone (GH) replacement, which was previously deemed contraindicated. Following the diagnosis of fatty liver, the patient began to exhibit liver damage that progressed over the ensuing years, ultimately leading to cirrhosis. Common factors linked to cirrhosis were excluded, leading to the belief that GH deficiency over several years was the primary contributor to cirrhosis. Therefore, when treating patients with GH insufficiency and diabetes, clinicians should carefully consider the potential implications of GH replacement therapy.